Cell kill kinetics of several nogalamycin analogs and adriamycin for Chinese hamster ovary, L1210 leukemia, and B16 melanoma cells in culture
- PMID: 7448758
Cell kill kinetics of several nogalamycin analogs and adriamycin for Chinese hamster ovary, L1210 leukemia, and B16 melanoma cells in culture
Abstract
Nogalamycin is an anthracycline antibiotic which was markedly cytotoxic in vitro and was active against several tumor systems in vivo. We compare here the lethality of several nogalamycin analogs against Chinese hamster ovary (CHO), mouse leukemia (L1210), and mouse melanoma (B16) cells in culture. 7-con-O-Methylnogarol (7-con-OMEN) was the most lethal of all the analogs tested. Thus, for CHO cells exposed for two hr to the drug, the 50% lethal doses of 7-con-OMEN, nogalamycin, and dis-nogamycin were 0.25, 2.7, and 5.8 micrograms/ml, respectively. In general, CHO cells were less sensitive than B16 or L1210 cells to most compounds. All compounds gave dose-survival curves which consisted of a shoulder region followed by a region of exponential decline in survival. The nogalamycin analogs nogalamycin, dis-nogamycin, 7-con-O-methylnogalarol, and 7-con-OMEN were selected for further study because of their greater lethality in vitro and antitumor activity in vivo. The lethality of these compounds was compared to that of Adriamycin. 7-con-OMEN was more toxic to CHO cells than was Adriamycin but was less toxic to B16 and L1210 cells. All of these compounds (except 7-con-O-methylnogalarol which was not tested) were more lethal to exponentially growing cells than to plateau-phase cells. The survival response after different periods of exposure to these drugs was compared. In order to make valid comparisons of the time-survival response to different drugs, the drug concentrations chosen were such that they were equitoxic after a two-hr exposure. Under these conditions, the order of lethality after long-term exposure (8 hr to 24 hr) was nogalamycin > dis-nogamycin > 7-con-OMEN, Adriamycin > 7-con-O-methylnogalarol. With all the drugs, the rate of cell death increased with increasing drug concentrations.
Similar articles
-
Lethality of nogalamycin, nogalamycin analogs, and adriamycin to cells in different cell cycle phases.Cancer Res. 1980 Oct;40(10):3437-42. Cancer Res. 1980. PMID: 7438031
-
Effect of 7-con-O-methylnogarol on DNA synthesis, survival, and cell cycle progression of Chinese hamster ovary cells.Cancer Res. 1981 Dec;41(12 Pt 1):4981-7. Cancer Res. 1981. PMID: 6458356
-
Treatment of mouse tumors with 7-con-O-methylnogarol and other analogs of the anthracycline antibiotic, nogalamycin.Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1971-8. Cancer Treat Rep. 1979. PMID: 526931
-
Kinetics of cell kill by hyperthermia.Cancer Res. 1979 Jun;39(6 Pt 2):2277-84. Cancer Res. 1979. PMID: 376117 Review.
-
The biochemical pharmacology of nogalamycin and its derivatives.Pharmacol Ther. 1991;51(2):239-55. doi: 10.1016/0163-7258(91)90080-6. Pharmacol Ther. 1991. PMID: 1838416 Review.
Cited by
-
Cytotoxicity of combinations of prostaglandin D2 (PGD2) and antitumor drugs for B16 melanoma cells in culture.Invest New Drugs. 1986;4(4):315-23. doi: 10.1007/BF00173504. Invest New Drugs. 1986. PMID: 3473056
-
Synergistic combination of menogarol and melphalan and other two drug combinations.Invest New Drugs. 1985;3(3):233-44. doi: 10.1007/BF00179427. Invest New Drugs. 1985. PMID: 2933360
-
Menogaril: a new anthracycline agent entering clinical trials.Invest New Drugs. 1984;2(4):359-67. doi: 10.1007/BF00171586. Invest New Drugs. 1984. PMID: 6239835 Clinical Trial.
-
Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro.Cancer Chemother Pharmacol. 1985;14(3):194-201. doi: 10.1007/BF00258115. Cancer Chemother Pharmacol. 1985. PMID: 3858013